Skip to main content

Table 2 Changes in baseline characteristics seen after treatment with carvedilol.

From: Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized study

  Before carvedilol
(N = 9)
After carvedilol
(N = 9)
% Change after treatment P-value
Body weight (kg) 89.72 ± 7.10 90.32 ± 7.39 0.6% 0.43
BMI (Kg/m²) 29.26 ± 1.76 29.48 ± 1.87 o.8% 0.39
Systolic BP (mm Hg) 142.4 ± 5.09 136.9 ± 5.80 -3.7% 0.38
Diastolic BP (mm Hg) 71.4 ± 2.59 61.3 ± 3.13³ -14.1% 0.003
Heart rate (beats/min) 67.1 ± 2.16 60.7 ± 1.74³ -9.5% 0.02
Fasting glucose (mmol/L) 8.61 ± 0.78 9.66 ± 1.31 12.2% 0.20
Fasting insulin (μU/L) 10.20 ± 3.20 13.75 ± 8.42 34.8% 0.68
Hb A1c (%) 7.6 ± 0.59 7.66 ± 0.76 0.8% 0.95
Total Cholesterol (mmol/L) 4.12 ± 0.28 4.48 ± 0.35 8.7% 0.06
LDL (mmol/L) 2.29 ± 0.31 2.5 ± 0.30 9.2% 0.10
HDL (mmol/L) 1.19 ± 0.06 1.24 ± 0.09 4.2% 0.37
TG (mmol/L) 1.41 ± 0.27 1.57 ± 0.28 11.3% 0.38
CRP (mmol/L) 3.00 ± 0.44 2.89 ± 0.26 -3.7% 0.68
  1. T2DM: Patients with Type 2 Diabetes; M/F: Male/Female; ACE inhibitors: Angiotensin Converting Enzyme inhibitors; AT2B: Angiotensin 2 Blockers; BMI: Body Mass Index, BP: Blood Pressure; Hb A1c: Glycosylated Hemoglobin A1c; LDL: Low Density Lipoprotein; HDL: High Density Lipoprotein; TG: TriGlyceride; CRP: C-Reactive Protein.